Brief: Australia's ACCC Says Zoetis' Acquisition Of Neogen Genomics Requires Phase 2 Review
17/07/2026 11:15
BRIEF-Australia's ACCC Says Zoetis' Acquisition Of Neogen Genomics Requires Phase 2 Review July 17 (Reuters) - Australia's ACCC:
ZOETIS’ ACQUISITION OF NEOGEN GENOMICS REQUIRES PHASE 2 REVIEW
ALSO CONSIDERING COMPETITIVE SIGNIFICANCE OF ZOETIS OBTAINING ACCESS TO INCREASED VOLUME OF GENETIC DATA ON CATTLE IN AUSTRALIA UNDER DEAL
NOT REACHED CONCLUSION ON ISSUES, WILL CONTINUE TO CONSIDER ACQUISITION OF NEOGEN IN PHASE 2
INVITES SUBMISSIONS IN RESPONSE TO ITS PHASE 2 NOTICE BY 31 JULY ON ZOETIS’ ACQUISITION OF NEOGEN
Further company coverage: ZTS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies